We’ve been waiting on this one for three years. If you’ve frequented this blog, you know three years is basically an eternity in Food and Drug Administration (FDA) years but a blink of an eye in cannabis-and-psychedelics-regulatory years. On July 14, 2026, FDA finally published its final guidance titled “Psychedelic Drugs: Considerations for Clinical Investigations,”
Longtime Budding Trends readers know we try to lead each post with a bit of pop culture or witty turn of phrase. This is one of those posts where the hook took longer to find than the law. Turns out there isn’t a great classic rock anthem about assisted living facilities’ admissions policies. So, we’re
If an employee uses marijuana off the clock and the employer doesn’t test for marijuana, isn’t it much like the tree falling in the woods?
A recent Wall Street Journal report (“More U.S. Workers Are Testing Positive for Marijuana. Fewer Employers Are Concerned,” July 10, 2026) suggests that is the case, laying out data that
Raising money in the cannabis industry, like most everything else in the space, is no walk in the park and presents a landmine for those tasked with raising and spending capital. This month, two federal district court opinions reminded capital raisers of these truths and the dire consequences of violating securities laws. In the first
In the summer of 2017, Phish lit up Madison Square Garden with a historic 13-night run. Your friends at Budding Trends believe the marijuana rescheduling decision calls for a rollout just as monumental, so we’ve created the Budding Trends Baker’s Dozen as a fitting homage.
Following the federal government’s move to reschedule medical marijuana from
“What a long, strange trip it’s been.”
When we launched Budding Trends years ago as a modest little blog focused on cannabis law, the idea that we’d one day spend serious time tracking potential widespread access to psychedelics was, to put it mildly, not part of the original pitch deck. And yet, here we are.
This is the tenth of 13 posts describing the impacts of marijuana’s rescheduling. An homage to Phish’s historic run at Madison Square Garden in the Summer of 2017, Budding Trends Baker’s Dozen will address how rescheduling affects various areas of the law and our daily lives. Enjoy the run.
There were massive cheers in the
This is the ninth of 13 posts describing the impacts of marijuana’s rescheduling. An homage to Phish’s historic run at Madison Square Garden in the Summer of 2017, Budding Trends Baker’s Dozen will address how rescheduling affects various areas of the law and our daily lives. Enjoy the run.
On April 22, 2026, Acting Attorney
This is the eighth of 13 posts describing the impacts of marijuana’s rescheduling. An homage to Phish’s historic run at Madison Square Garden in the Summer of 2017, Budding Trends Baker’s Dozen will address how rescheduling affects various areas of the law and our daily lives. Enjoy the run.
Another industry that isn’t currently in
After years of false starts, stalled hearings, a retired judge, a fired attorney general, and a president who last weekend told officials to stop “slow-walking” on cannabis, we finally have something to talk about. Effective April 22, 2026, Acting Attorney General Todd Blanche signed a final order moving FDA-approved marijuana products and state-licensed medical marijuana